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Abstract
Background: Dengue fever is the most common and widespread mosquito-borne arboviral disease in the world.
There is a compelling need for cost-effective approaches and practical tools that can reliably measure real-time
dengue transmission dynamics that enable more accurate and useful predictions of incidence and outbreaks.
Sensitive surveillance tools do not exist today, and only a small handful of new control strategies are available.
Vector control remains at the forefront for combating dengue transmission. However, the effectiveness of many
current vector control interventions is fraught with inherent weaknesses. No single vector control method is
effective enough to control both vector populations and disease transmission. Evaluations of novel larval and adult
control interventions are needed.
Methods/design: A cluster-randomized controlled trial will be carried out between 2017 and 2019 in urban
community clusters in Khon Kaen and Roi Et cities, northeastern Thailand. The effectiveness of a pyriproxyfen/
spinosad combination treatment of permanent water storage containers will be evaluated on epidemiological and
entomological outcomes, including dengue incidence, number of female adult dengue vectors infected or not
infected with dengue virus (DENV), human exposure to Aedes mosquito bites, and several other indices. These
indices will also be used to develop predictive models for dengue transmission and impending outbreaks.
Epidemiological and entomological data will be collected continuously for 2 years, with the intervention
implemented after 1 year.
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Discussion: The aims of the trial are to simultaneously evaluate the efficacy of an innovative dengue vector control
intervention and developing predictive dengue models. Assessment of human exposure to mosquito bites by
detecting antibodies generated against Aedes saliva proteins in human blood samples has, so far, not been applied
in dengue epidemiological risk assessment and disease surveillance methodologies. Likewise, DENV detection in
mosquitoes (adult and immature stages) has not been used in any practical way for routine disease surveillance
strategies. The integration of multiple outcome measures will assist health authorities to better predict outbreaks for
planning and applying focal and timely interventions. The trial outcomes will not only be important for Thailand,
but also for the entire Southeast Asian region and further afield.
Trial registration: ISRCTN, ISRCTN73606171. Registered on 23 June 2017.
Keywords: Dengue monitoring, Entomology, Immunology, Dengue index, Risk assessment, Vector control
Background
Dengue fever is the most common and widespread arbo-
viral disease in the world, with an estimated four billion
people in at least 128 countries at risk of infection [1].
The exact global burden of dengue is not known, but
there are estimates of about 390 million infections annu-
ally, of which only a minority (~ 25%) manifest clinically
[2]. Yearly mortality figures of > 20,000 deaths have been
reported [3]. Dengue fever and other arboviral diseases,
such as Zika and chikungunya, are transmitted to
humans primarily by Aedes aegypti and Aedes albopictus
mosquitoes. There is currently no specific treatment for
dengue and only recently has a vaccine been licensed,
but it does not confer full protection for all virus sero-
types [4]. Even with effective therapies and vaccines, vec-
tor control will likely remain important to curtail disease
incidence and outbreaks. Perennial dengue incidence
varies seasonally, and dengue outbreaks occur periodic-
ally in most endemic countries [5]. Infection of one of
the four dengue virus serotypes (DENV1—4) typically
confer lifelong protective homotypic (type-specific)
immunity as well as production of more time-limited
cross-reactive heterotypic neutralizing antibodies [6];
however, antibody-dependent enhancement may result
in a second DENV serotype infection inducing a more
severe clinical course [5].
For improved dengue control, reliable epidemic fore-
casting systems for early detection of temporal anomal-
ies in disease incidence are needed, as well as more
effective control strategies that affect both entomological
and epidemiological endpoints. Sensitive surveillance
tools do not exist today, and only a small handful of new
control strategies are available [7–14]. For example, al-
though temephos — the most commonly used chemical-
based vector control method, used against immature
mosquito stages — may be effective in reducing entomo-
logical indices, there is no evidence showing it reduces
dengue transmission [7].
There is a compelling need to develop cost-effective
approaches and practical tools that can reliably measure
real-time dengue transmission dynamics that enable
more accurate and useful predictions of outbreaks. Cur-
rently, there is no universally accepted definition of what
constitutes an outbreak [15]. This complicates the inter-
pretation of early detection of cases that exceed expected
normal seasonal variations. In many endemic countries,
a dengue outbreak is declared when the number of
reported cases during a specific time period (week or
month) surpasses the historical average of the preceding
5 to 7 years above two standard deviations (SD), known
as the endemic channel [5]. Outbreak definitions vary
depending on how the historical average is calculated,
which may involve, for example, the number of years
used, type of mean (e.g., monthly or moving mean),
whether or not outbreak years are included, how the
critical threshold is calculated (e.g., ±2 SD), and criteria
used to define the outbreak (e.g., time above the thresh-
old before a response is triggered) [15]. Ideally, when an
outbreak alert has been triggered, standard vector con-
trol strategies should be implemented. However, current
early warning systems and detection of outbreaks are
usually neither accurate nor timely enough to initiate
effective control interventions (outbreak response) to
curb increased transmission after it has begun [11].
Various entomological indices are used to measure
dengue vector infestation in and around structures
(homes, buildings, etc.). However, these indices are sel-
dom sensitive enough to precisely estimate dengue
transmission risk or predict impending outbreaks [16,
17]. The Stegomyia indices, i.e., House index (HI, pro-
portion of Aedes positive houses) and Container index
(CI, proportion of Aedes positive containers) were devel-
oped nearly a century ago [18], followed by the Breteau
index (BI, number of Aedes positive containers per 100
houses) [19]. These three measures are currently the
most commonly used indices to assess dengue vector
larval habitat infestations. They are relatively easy to
measure, but are generally not correlated with disease
incidence or outbreak risk [16]. In the 1990s, Focks et al.
explored the use of pupal surveys as a potentially more
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epidemiologically relevant index, correlating total pupal
densities with resultant adult densities [20]. This led to
further development of entomological thresholds using a
pupal/demographic method, ambient temperature, and
seroprevalence of dengue antibodies in the population
[21]. As a result, container-specific, targeted source re-
duction was proposed by identifying the relative import-
ance of major types of container habitats with high
pupal productivity that contribute significantly to the
transmission threshold [21]. However, it remains unclear
if targeting only containers that are responsible for the
vast majority, say 80–90%, of the pupal production [22–
26] is sufficient to have an epidemiological impact on
transmission. Other aquatic habitats may be important,
such as unusual and cryptic sites, which are typically
overlooked during vector control interventions [27, 28].
Furthermore, in many settings, such as in northeastern
Thailand and southern Laos, as many as eight to ten of
the most productive container types might only produce
< 70% of all pupae [29]. Although there are perceived
benefits to targeting only the most productive con-
tainers, such as reduced time and effort, they may not
compensate for ignoring control of other less obvious
breeding habitats. The difficulty in finding and effect-
ively treating such cryptic sites can be addressed by
using pyriproxyfen, a potent insect growth regulator,
which can be transferred between habitats by female Ae-
des mosquitoes during oviposition, a strategy called
auto-dissemination [30–32].
A recent study from Iquitos, Peru investigated the
relationship between several indicators of Ae. aegypti
abundance and DENV infection in humans using more
than 8000 paired serological samples with corresponding
entomological data [17]. The researchers found that in-
dicators based on cross-sectional entomological surveil-
lance, i.e., data from a single survey observation, are of
little practical use. On the other hand, longitudinal-
based, household-level entomological indicators using
data from up to three yearly visits before a 6-month
seroconversion period showed that the presence of adult
female Ae. aegypti in a household increased the risk of
DENV seroconversion by approximately 29% compared
to households without mosquito vectors. The authors
therefore challenged the assumption that most common
Ae. aegypti indicators provide adequate proxies for
DENV risk and transmission [17].
The general response by national dengue control pro-
grams to indications of increased disease transmission
and possible outbreaks mainly consists of reactive vector
control. Typically, control activities involve application
of temephos (an organophosphate compound) to domes-
tic water storage containers for larval control and/or
peridomestic space spraying with an insecticide, most
commonly a pyrethroid-based formulation, for adult
control. Although, these interventions may reduce vector
populations dramatically, there is no evidence that they
reduce dengue transmission substantially [7, 9]. Other
possible options for vector control are community-based
source reduction campaigns, application of bacteria-based
larvicides, larvivorous fish, or copepods, or combinations
of these approaches [8, 33–35]. Newer paradigms for
Aedes vector control include microbial control of human
pathogens in adult vectors, such as Wolbachia bacteria
that shorten the lifespan of mosquitoes [36] and release of
transgenic Ae. aegypti engineered to carry a dominant
lethal gene that suppresses mosquito populations [37].
These novel approaches are currently not recommended
for full-scale programmatic deployment by the World
Health Organization (WHO) Vector Control Advisory
Group, but rather implemented as carefully planned pilot
interventions under operational conditions [38]. The ef-
fectiveness of many vector control interventions is fraught
with inherent weaknesses, e.g., widespread insecticide re-
sistance, quality of delivery, and other operational issues,
such as availability and cost of insecticide, dedicated and
trained personnel, and appropriate application equipment
[39, 40].
The WHO Global Strategic Framework for integrated
vector management (IVM) was released in 2004 and
recommends a range of interventions, in combination,
to increase impact [41]. This means there is no single
vector control method that is effective enough to control
both vector populations and disease transmission. Com-
binations of larval control interventions, such as mix-
tures of pyriproxyfen (an insect growth regulator) and
spinosad (a biopesticide) have been evaluated. This com-
bination reduced larval and pupal relative densities by
90% for at least 4 months in the French West Indies
[42]. Pyriproxyfen, even in minute doses, can induce
complete inhibition of adult emergence for several weeks
after treatment [43]. Pyriproxyfen used alone and
applied to storm drains in Colombia reduced dengue
cases by 80% [44]. The benefit of using these two com-
pounds in combination is that they have different modes
of action and that pyriproxyfen targets the pupal stage
while spinosad is active against larval stages. Both com-
pounds have very low toxicity for humans and most other
non-target fauna [45, 46]. The WHO draft on global vec-
tor control response for 2017–2030 [47] builds on the
IVM approach but places stronger emphasis on enhancing
human capacity and health education, increasing research
and innovation by strengthening infrastructure, and
increasing intersectoral and interdisciplinary action. The
targets of the global response are to reduce mortality and
incidence due to all vector-borne diseases globally relative
to 2016 by at least 75% and 60%, respectively.
In view of the preceding discussion, this study aims to
assess a specific vector control intervention and to
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contribute to the development of a practical early warn-
ing system that can more accurately predict changes in
dengue transmission and impending outbreaks. The trial
will determine the efficacy of a pyriproxyfen/spinosad
combination in water storage containers to reduce ento-
mological risk indicators and dengue incidence. The
hypothesis is that the study arm receiving the combin-
ation treatment in household water storage containers
will have a lower density of adult female Ae. aegypti per
house, both indoors and outdoors, compared to the
study arm receiving an alternative intervention involving
normal governmental action. Furthermore, the study
aims to determine one or more entomological indices
and an immunological index that best predicts dengue
incidence for the study area.
Methods/design
Objectives
The specific objectives of this trial are to:
1. Assess the effect of periodically treating water
storage containers with a pyriproxyfen/spinosad
combination on entomological and epidemiological
outcomes
2. Determine the most accurate and precise index or
indices to predict variation in dengue incidence in
time
Trial design
A stratified, cluster-randomized controlled trial is de-
signed to study the effect of a vector control interven-
tion in households located in pre-selected clusters in
two urban areas in northeastern Thailand. Each cluster
is randomized to one of two arms: intervention clusters
receiving treatment of water containers with a pyriprox-
yfen/spinosad combination, and control clusters not
receiving any intervention from this project. Control
areas will rely on normal operational vector control
interventions performed by the local public services.
Randomization of arms is stratified by city (Khon Kaen
and Roi Et, i.e., two levels). Stratification is done because
there are potential differences between the two cities
that may affect the outcomes (e.g., population size, and
regional importance in terms of travel, commerce,
services, health care, and education); therefore, stratifica-
tion may reduce the residual statistical error when one
compares the two arms. Including two cities may also
alleviate problems of low incidence caused by the spatial
and temporal variation in dengue transmission; i.e., one
area functions as a backup if there are few cases in the
other. Including two cities should also increase the
generalizability of the trial.
A cluster design is considered the best option because
the intervention is not performed on the individual level,
but is rather a spatial, area-wide approach involving
treatment of containers in and immediately around each
house and property in a study area (cluster). Within a
household, it is not feasible to randomize some individ-
uals to one intervention and other individuals to an-
other. Furthermore, the entomological outcomes, both
primary (Adult index) and secondary (e.g., Pupal index
per person, and the Breteau index), will be estimated on
a household level. We are using the larger clusters rather
than single houses because (1) there may be mass (area)
effects of the interventions, whereby entomological indi-
ces in each house may depend partly on the abundance
of mosquitoes in neighboring ones, and (2) entire clus-
ters having the same intervention more closely resem-
bles how the intervention would be implemented,
should it be scaled up.
Setting
The trial is carried out in two urban areas, Khon Kaen
(N16.440236, E102.828272) and Roi Et (N16.055637,
E103.652417) cities in northeastern Thailand (Fig. 1).
Khon Kaen is the capital city of the province with the
same name. The province has an area of ~ 10,900 km2,
divided into 26 districts and a population of 1,741,980 in
the 2010 national census [48]. Khon Kaen district is the
largest by area and population, with a population of
around 400,000 over an area of 953.4 km2 (population
density 416 persons/km2). The district is divided into 17
sub-districts with 272 villages. In 2016, there was a
population of 269,247 in six sub-districts that make up
greater Khon Kaen (within the ring road) with a resident
density of 2500/km2 in the central parts. Roi Et is the
capital city of Roi Et province and is divided into 20 dis-
tricts covering a total area of 8300 km2 with a popula-
tion of 1,084,985 in 2010 [48].The largest district is also
called Roi Et, and it has ~ 160,000 inhabitants, covers an
area of 493.6 km2, and has a population density of
approximately 311 inhabitants/km2. There are 15 sub-
districts and 195 villages in Roi Et district. The largest
sub-district is Nai Mueang Roi Et municipality with a
population of approximately 34,000 inhabitants. To
delimit the study area, only villages completely within
each city’s primary access ring road are selected. We use
the English word “village”, although most are urban
divisions. In Khon Kaen, there are 162 villages in six
sub-districts within the ring road. In Roi Et, there are 56
villages in nine sub-districts within the ring road,
although only 39 have clearly demarcated administrative
boundaries.
Between 2006 and 2016, the total number of reported
dengue cases (uncomplicated and severe categories)
reported in Khon Kaen province was 15,195 (mean 1381
cases/year, range 439–3014), providing an incidence rate
of 76.7 cases/100,000 population. In Khon Kaen district,
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the number of cases during the same period was 7209
(mean 655 cases/year, range 204–1705), with an estimated
incidence of 455.3 cases/100,000. The corresponding num-
bers for Roi Et province for the same period were 20,174
total cases (mean 1834 cases/year, range 402–4141) and an
incidence of 140.2 cases/100,000. In Roi Et district, 3956
cases were reported during the period (mean 360 cases/
year, range 71–914) with an incidence of 329.1 cases/
100,000. All dengue case data were provided by the Office
of Disease Prevention and Control Region 7, Khon Kaen,
Ministry of Public Health.
Outcomes
The primary outcome is the Adult index (AI, the
number of female adult Ae. aegypti and Ae. albopictus
collected per house) (Table 1). The AI is based on com-
bined indoor and outdoor collections using mechanical,
battery-powered aspirators for 30 min (2 × 15 min) by
staff of the local public health departments. The AI for
each species will be recorded separately, although the
general expectation is to find a predominance of Ae.
aegypti in all urbanized clusters.
The secondary outcomes are the dengue incidence rate
(DIR), mosquito exposure index (MEI), infected adult
index (IAI), adult sticky trap index (ASTI), pupae per
person index (PPI) and BI (Table 1). Dengue cases (inci-
dence) is a secondary endpoint, because the sample size
required to detect a difference would be unfeasibly large.
In addition to the intervention-related outcomes, the
study will attempt to predict dengue incidence over time
using entomological and immunological indices. The
main outcomes for this part are identification of mea-
sures (indices) with sufficient accuracy and precision in
terms of predicting dengue outbreaks as defined by the
Ministry of Public Health.
Sample size
The sample size is calculated based on data on adult
female Aedes mosquitoes collected using mechanical
aspirators (15 min outdoors and indoors each) from a
case-control study in nearby districts during 2016 and
2017. The mean capture was 0.78 mosquito per house
(indoors + outdoors). At minimum, 34 clusters are
needed to detect a 90% difference in adult female
mosquitoes per house with 90% statistical power and a
two-sided significance level (α) of 0.05 assuming 10
households are visited three times each after the inter-
vention begins and a between-cluster coefficient of
variation of 0.33. Sample size methods for cluster-
randomized trials were used [49], as implemented in the
‘clustersampsi’ add-on to Stata® statistical software [50].
The existing data were over-dispersed relative to a
Poisson distribution; therefore, to represent a negative
binomial distribution with a dispersion parameter (α, or
1/k) of 2.03 estimated from the same data, the ‘means’
option was used, with the variance in each arm equal to
the mean plus the square of the mean times α [51]. The
Fig. 1 Study locations in northeastern Thailand. The red borders around the cities (right insets) are the respective ring roads.
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Table 1 Primary and secondary outcome measures and other entomological indices
Outcome No. Index
abbreviation
Index
name
Description Unit Frequency of data collection Details
Primary
outcome
1 AI Adult
index
Number of female adult
Ae. aegypti and Ae.
albopictus per house
collected both indoors
and outdoors
No./
house
Once every 4 months in all
households (HHs) and once
every month in 3 HHs per
cluster (the same ones each time)
Adult collections using a
mechanical battery-powered
aspirator for 30 min per house
(indoors and outdoors)
Secondary
outcomes
2 DIR Dengue
incidence
rate
Number of confirmed
dengue cases/
observation days of
household populations
Rate Weekly VHVs detect fever cases.
Hospital and project staff
collect blood samples
3 MEI Mosquito
exposure
index
(1) Differential optical
density for antibodies to
Ae. aegypti saliva
(2) Proportion above
the immune threshold
for this assay
(1)
Number
(2) %
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster (the same HH as
for the AI)
Recurring blood spots from
two persons per HH taken
on filter paper. IgG antibody
response (positive or negative)
to the Ae. aegypti Nterm-34
kDa salivary peptide
4 IAI Infected
adult
index
Number of DENV-
infected adult female
Ae. aegypti and Ae. albopictus
No./
house
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Based on adult mosquito
collections indoors using a
mechanical battery-powered
aspirator for 15 min per house
and DENV detection in
individual mosquitoes
5 ASTI Adult
sticky trap
index
Total number of Ae.
aegypti and Ae.
albopictus females
collected by sticky traps
per month
No./trap/
month
7 consecutive days per month Adult mosquitoes collected
by sticky traps baited with
hay infusion for 7 days
every month
6 PPI Pupae per
person
index
Number of Aedes pupae
per person
No./
person
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
From immature collections.
All pupae collected divided
by the number of household
participants
7 BI Breteau
index
Number of Aedes
positive containers per
100 houses
No./100
houses
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
From immature collections.
Cluster-level result
Stegomyia
indices
8 HI House
index
Proportion of houses
positive for immature Aedes
% Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
From immature collections.
Cluster-level result
9 CI Container
index
Proportion of containers
positive for immature Aedes
% Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
From immature collections.
Cluster-level result
Pupal
indices
10 IPPI Infected
pupae per
person
index
Number of DENV
infected Aedes pupae
per person
No./
person
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Based on PPI and DENV
detection. All infected pupae
collected divided by the
number of household
participants
11 PHI Pupae per
house
index
Number of pupae
per house
No./
house
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Pupal collections
12 IPHI Infected
pupae per
house
index
Number of DENV-
infected Aedes pupae
per house
No./
house
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Pupal collections and
DENV detection
Adult
indices
13 AII Adult
indoor
index
Number of Ae. aegypti
and Ae. albopictus
females per house
indoors
No./
house
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Adult collections indoors using
a mechanical battery-powered
aspirator for 15 min per house
14 IAII Infected
adult
indoor
index
Number of DENV-
infected Ae. aegypti and
Ae. albopictus females
per house indoors
No./
house
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Based on AII and
DENV detection
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clusters are split equally between the strata (Khon Kaen
and Roi Et). To provide an equal number of clusters in
each arm, one extra cluster is added per stratum, i.e.,
18 clusters per stratum (city) and 9 clusters per arm in
each stratum.
Eligibility criteria
Eligibility for participation in the trial is determined on
four levels: (1) location or village, (2) cluster of houses
within village, (3) households within cluster, and (4)
individuals within households (household residents)
(Table 2).
Recruitment
The 162 villages in Khon Kaen and 39 villages in Roi Et
located within the respective ring roads are the sampling
frames for each stratum. In each stratum, villages are
randomly sampled based on probability proportional to
population size, i.e., the population of occupied houses
(the target denominator of the primary endpoint). These
Table 1 Primary and secondary outcome measures and other entomological indices (Continued)
Outcome No. Index
abbreviation
Index
name
Description Unit Frequency of data collection Details
15 AOI Adult
outdoor
index
Number of Ae. aegypti and
Ae. albopictus females per
house outdoors
No./
house
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Adult collections outdoors
using a mechanical battery-
powered aspirator for
15 min per house
16 IAOI Infected
adult
outdoor
index
Number of DENV-infected
Ae. aegypti and Ae. albopictus
females per house outdoors
No./
house
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Based on AOI and
DENV detection
17 IASTI Infected
adult
sticky trap
index
Number of DENV-infected
Ae. aegypti and Ae. albopictus
females per sticky trap
No./trap/
week
Once every 4 months in all HHs
and once every month in 3 HHs
per cluster
Based on ASTI and
DENV detection
Premise
index
18 PCI Premise
condition
index
Degree of shade + condition
of house + condition of yard
Number
(min = 3,
max 9)
Once every 4 months in all HHs Observation criteria [90]
VHV village health volunteer, IgG immunoglobulin G
Table 2 Eligibility criteria by location, cluster, household, and individual
Level Inclusion criteria Exclusion criteria
Village - Within ring roads of each city (stratum) - Area < 0.125 km2
- Populated residential areas - Number of houses < 100
- Population < 300
- Coverage of residential area 70–80% (scattered housing)
- Non-residential areas, e.g., agricultural fields, airports,
industrial areas, commercial areas, (e.g., shopping malls),
government offices, lakes, army camps, hospitals, and schools
Cluster - All points of the cluster are at least 100 m from
the nearest point of the village border
Household - Households that are permanently inhabited - Apartment buildings
- Abandoned houses
- Households that are built or re-populated during
the study period
- Non-permanent households
Individual - Individuals in households where household head has signed
informed consent for household to participate in project
- A travel history outside the village during the previous 7 days
- Self-reported fever within the last 7 days - Chronic disease, such as HIV/AIDS, or other health
condition that preclude participation in the study
- Age ≥ 1 year old - Apparent inability to give informed consent,
e.g., due to mental disability
There is a distinction between being included in the final evaluation of endpoints and inclusion for receiving interventions. For example, abandoned houses and
non-permanent household structures are not included in evaluation of endpoints, but they may be treated with an intervention if they are located within a radius
of 100 m and as feasibly possible
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selected villages will be randomly allocated between the
arms (see the section on Assignment of interventions
below).
Villages are normally much larger than the target clus-
ter size (10 houses); therefore, to select a starting point
for the house selection, a 50 × 50 m grid and a 100-m
buffer zone inside of the village perimeter will be super-
imposed over each village map. The buffer zone of
approximately 100 m on the inside of each village border
is applied to reduce potential “contamination” (in-flying
mosquitoes) from neighboring villages. A random grid
cell is selected in each village and 10 houses nearest the
centroid of that cell selected. This procedure is followed
in each village in this manner as far as practically
possible. For example, if a selected household does not
want to participate in the study, a neighboring house will
be selected.
Informational meetings are held at the sub-district and
village administrative levels to provide information about
the project and benefits to the communities. House-
holders are visited and carefully informed about the
study, and informed consent is obtained from the house-
hold head. A complete enumeration of all participants in
the selected clusters will be completed with assistance
from the local administration and village health volun-
teers (VHVs). This enumeration will be done three times
during the study, allowing monitoring of potential
participants’ discontinuation in the trial. Data on discon-
tinuation, whether due to movement outside the study
area or withdrawal of consent, are relevant for the
secondary outcomes of DIR and MEI. Reasons for
potential discontinuation will be monitored and taken
into account in communication strategies to promote
retention. In addition, a minor monetary compensation
for those who provide blood samples for the mosquito
exposure study will promote participant retention to
complete follow-up of individuals.
Interventions
Following approximately 10–12 months of baseline data
collections, household interventions will begin in the
selected intervention clusters (Fig. 2). The intervention
specifically targets mosquito immature stages by applying
a mixture of pyriproxyfen and spinosad to all permanent
household containers, whether indoor or outdoor, found
to contain water up to a 10-m perimeter from the house.
Pyriproxyfen is an insect growth regulator (insect juvenile
hormone analog) that is active against pupal stages, result-
ing in the inhibition of adult development (preventing
emergence). It has low mammal toxicity and is recom-
mended by WHO for vector control [52]. Spinosad is a
natural insecticide produced by the soil bacterium
Saccharopolyspora spinosa. It has a neurotoxic mode of ac-
tion in insects, but with low mammal toxicity, and it is also
recommended by WHO [52]. The doses recommended by
WHO for Aedes immature mosquito control are 0.01 mg/L
active ingredient (a.i.) pyriproxyfen (applied as a 0.5%
granule formulation) and 0.1–0.5 mg/L a.i. spinosad
(also a 0.5% granule formulation) [45, 53]. Both pyri-
proxyfen and spinosad have also been assessed and
approved by WHO for use in drinking water containers
[54, 55]. The reasons for selecting this novel intervention
are that the combination of pyriproxyfen and spinosad has
not yet been tested in a national dengue vector control
program; that it should be effective, easy, and practical to
use for national control authorities; and that its combined
Fig. 2 Time schedule of enrollment, interventions, and pre- and post-allocation data collections (based on SPIRIT 2013 figure [91])
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use reduces the risk of resistance development. The inter-
ventions will be implemented by project staff from the
Ministry of Public Health, thereby ensuring adherence to
intervention protocols.
The combination larvicide will be applied simultan-
eously to containers every 3 months. A buffer zone of
approximately 100 m will be established around the
selected intervention clusters. All selected households
and other households inside this buffer zone will be
treated. As far as feasibly possible, abandoned house-
holds, non-permanent households, non-occupied prop-
erties, and vacant lots inside the buffer zone will be
treated in the same manner.
The households in the other half — the control arm
clusters — will not receive any specific intervention ini-
tiated by the project. However, for ethical reasons, the
comparator, i.e., the control arm, will receive normal
governmental dengue control activities. Therefore,
during the study period, both intervention and control
clusters may be subjected to governmental action as part
of the existing national dengue control program
response. This may consist of space spraying with pyre-
throids in and around a household where a dengue
(index) case has been reported, including surrounding
houses within a radius of 100 m from an index case.
Additionally, larval control with temephos applied to
household water-holding containers may occur. Larval
control activities depend on the availability of staff,
insecticides, and time. Although space spraying can be
used in clusters of either arm (e.g., if a dengue case is
detected), temephos will not be applied in the interven-
tion clusters to avoid biased results and concerns from
the public about potential negative effects on water qual-
ity. The pyriproxyfen/spinosad combination may be
more effective than temephos, particularly since teme-
phos resistance has been detected in Ae. aegypti in
several sites in Thailand [56].
Assignment of interventions
Sequence generation and implementation
The assignment of intervention (allocation) and control
to clusters will be accomplished by two open public
lottery events, one in each city (Fig. 2). Allocation will
be done several months after and independently from
cluster recruitment (Fig. 2). The lottery events will be
carried out just before the first intervention. Representa-
tives from each respective sub-district and village,
including householders, district village heads, VHVs, and
sub-district hospitals, will be invited to attend. Informa-
tion about dengue and the purpose of the project will be
provided. The reasons for randomization, its procedures,
and the concepts of intervention and control will be
explained. Attendants will also have a chance to ask
questions about dengue, vector control, health-seeking
behaviors, personal experiences of dengue, and specific
details about the project.
Each of the two lotteries will be performed as follows.
Small pieces of paper, of the same color and size and thus
indistinguishable from one another, numbered from 1 to
18, will be folded and placed in small opaque envelopes
and then placed in a bowl. Each number represents a clus-
ter (village). A large screen with the numbered list of vil-
lage names (from 1 to 18) will be shown above the bowl
and visible to all. A person not involved in the study,
and accepted by all participants, will be selected to
make the draw. Two flip boards with large sheets of
paper will be placed on either side of the bowl with
the respective headings “Intervention” and “Control”
(in Thai). The village on the first paper drawn will be
assigned to the intervention arm, the village on the
next paper drawn will be assigned to the control arm,
and so on. Following the draw, the implications of
being in either of the two arms will be discussed and
the roles of participants, health volunteers, and sub-
district hospital staff will be reviewed. By following
this lottery scheme, the interventions are allocated at
the same time as the sequence is generated, obviating
the need for allocation concealment.
Blinding
This study is unblinded for both participants and data
collectors because of the nature of the intervention and
because it is neither practical nor financially feasible to
obtain placebo (blank) granules of pyriproxyfen and
spinosad to serve as a control. However, although know-
ledge of treatment allocation could affect mosquito end-
points (e.g., differential collection efforts), the MEI,
which relies on the antibody response to Ae. aegypti
saliva, should not be affected significantly. In terms of
performance bias (i.e., systematic differences in care),
dengue incidence is an endpoint, and dengue may initi-
ate contact with health care personnel. However, the
subsequent course of the episode does not affect any of
the endpoints. In other words, care from health
personnel will not affect the dengue diagnosis status, so
performance bias should not be a concern.
Data collection
Household questionnaire
Following the consent (see more details later in the paper),
the household head will be asked to complete a question-
naire on the normal number of people living in the house,
their age and sex, and socioeconomic status, including ob-
servations of type and quality of house structure and facil-
ities. The household questionnaire will be repeated
annually. However, parts of the questionnaire relating to
vector control activities will be carried out every 4 months.
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Disease surveillance
VHVs will carry out weekly visits at participating house-
holds during the 24-month study period. At each visit,
household members will be asked about any fever epi-
sodes during the preceding week. Body temperature,
using an axilla (under-armpit) thermometer, will be mea-
sured by the VHVs in all subjects who have reported a
recent or current fever. In order to include people who
have a fever at times when the VHVs are not visiting,
household participants will be asked to call the VHVs by
telephone to inform them about this. In that case, the
VHV will attempt to visit the house immediately and
collect data and temperature from that person. If that is
not possible, this person will be included in the next
regular VHV visit. Subjects who have or have had a fever
(i.e., irrespective of body temperature at the time of the
visit) will be brought on the VHV’s motorcycle or by
other practical means to the collaborating sub-district
hospital and offered a blood test using a commercial
rapid diagnostic test kit (RDT: SD BIOLINE Dengue
Duo Combo device, cat. no. 11FK46; Standard Diagnostic
Inc., Suwon, Korea). This test is designed to detect dengue
non-structural protein 1 (NS1) antigen and immuno-
globulin M (IgM)/immunoglobulin G (IgG) antibodies.
An additional 4-mL blood sample and blood spots will be
taken for confirmation of DENV infection and serotype
determination. All blood samples will be collected by a
certified phlebotomist (or other qualified health staff ) in
accordance with national guidelines. All blood samples
will be transferred to the Department of Microbiology,
Khon Kaen University, where they will be processed for
serum separation and transferred to a –80 °C freezer to
await further processing. RNA extraction will be per-
formed using a QIAamp® Viral RNA Mini Kit (Qiagen,
Hilden, Germany) on serum samples. Extracted RNA will
be stored at –80 °C for viral detection and sequencing.
DENV will be confirmed by nucleic acid detection using
reverse transcription polymerase chain reaction (RT-PCR)
with DN-F and DN-R primers as described in Shu et al.
[57]. Data on potential risk factors, such as patient’s age,
travel history, and previous dengue infection history, will
be collected at time of blood sampling. Although not part
of the outcome factors, tests for Zika [58] and chikun-
gunya [59] infections will be performed using RT-PCR
and sequencing for confirmation.
Inclusion criteria for individuals The inclusion criteria
for individuals are as follows:
– Self-reported fever within the last 7 days
– Age ≥ 1 year old
Exclusion criteria for individuals The exclusion criteria
for individuals are as follows:
– A continuous travel history outside the district
during the last 7 days
– Diseases, such as HIV/AIDS or other health
conditions, that preclude participation in the study,
based on self-evaluation
– Apparent inability to give informed consent, e.g.,
due to mental disability or other incapacity, or lack
of a legally authorized representative
Exposure to mosquito bites
To assess the level of exposure to Aedes bites, blood
spots on filter paper will be taken from each person des-
ignated as a fever case (detected during the weekly visits)
for immunological analysis. In addition, recurring blood
spot collections will be taken from two additional indi-
viduals, ideally the same adult and child (5–14 years old)
each time. These collections will be done monthly in
each of three households per cluster and every 4 months
in all households per cluster. Individuals will be selected
based on their availability and willingness to participate
over the full course of the study; ideally, they will be
individuals who are present at home most of the time.
Participants providing blood spots will receive a minor
monetary compensation. As the immune background
will be variable between individuals, the same individuals
are needed to follow changes in their immune response
to Aedes bites over time. Blood samples will be taken
from people in their households by a certified phlebot-
omist (or other qualified health staff ) using a finger
prick. Two blood spots (2 × 75 μL) will be placed on
filter paper (Protein Card Saver 903™) and stored at 4 °C
until further analyses.
Blood samples will be eluted in phosphate-buffered
saline (PBS) with 0.1% Tween for 24 h at 4 °C and then
stored at –20 °C. The salivary peptide Nterm-34 kDa
(Genepep, St Clement de Rivière, France) will be used as
an Aedes-specific biomarker to quantify the immune
response to Ae. aegypti mosquito bites by immunoassays
[60]. Briefly, the peptide will be coated on a certified
plate (MAXISORP®; Nunc, Roskilde, Denmark), and the
blood samples will be incubated overnight at 4 °C to
allow specific IgG to bind to the salivary peptide. An
anti-human IgG secondary antibody enzyme conjugate
will be incubated to bind individual IgG attached to the
biomarker. Substrate will be added for color develop-
ment. The level of immune response will be assessed
by measuring the absorbance after 120 min at 405
nm (Sunrise™ spectrophotometer, Tecan, Männedorf,
Switzerland). Each sample will be compared in dupli-
cate wells and in a blank well (without antigen) to
measure non-specific reactions. Individual results will
be expressed as a differential optical density (ΔOD)
value calculated as ΔOD = ODx − ODn, where ODx
represents the mean of individual OD values in the
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two wells containing antigen, and ODn represents the
OD value in the well without antigen. Specific anti-
Nterm-34 kDa IgG response will be assayed in indi-
viduals who have not been exposed to Ae. aegypti
mosquitoes to quantify the non-specific background
antibody level and to calculate the specific immune
threshold (TR) as follows:
TR ¼ mean ΔODunexposed
 þ 3SD:
The main outcome for this immune response assay
will be ΔOD, which is a continuous variable. In addition,
a binary outcome will be calculated by considering an
individual to be “exposed” if the ΔOD value is higher
than the TR calculated from unexposed individuals.
Entomological collections
Mosquito collections will be carried out in all participat-
ing households every 4 months (Fig. 2). In addition,
monthly collections will be done in the three sentinel
households per cluster, using the same households as
those used for the blood spot collections for logistical
reasons. The following data will be recorded from each
household: number of total containers (potential breed-
ing sites, wet or dry), number of containers with water,
number of mosquito positive and negative containers
(any species), container type, and location (indoors/out-
doors) using defined criteria. Mosquito larvae will be
collected from all positive containers using a standard
larval dipper to determine species composition (both Ae.
aegypti and Ae. albopictus will be identified and
recorded). Pupae will be collected using the pupal/
demographic survey method [19] and the “five-sweep”
net procedure for very large containers [61].
Adult mosquitoes will be collected for 15 min indoors
(in living rooms, bedrooms, etc.) and 15 min outdoors
(among man-made articles, vegetation, etc.) from each
household using a Prokopack mechanical aspirator [62].
Adult mosquitoes will also be collected using stationary
sticky lure gravid Aedes traps [63] placed in a location
where mosquitoes are abundant (based on householders’
knowledge) at four selected households for 7 consecutive
days every month. Specimens will be taken to a labora-
tory for sorting and identification using a stereomicro-
scope and morphological keys [64, 65]. Larvae
(separated by species) and pupae (separated by species
and sex) will be stored in absolute 99.5% ethanol in la-
beled 1.5-mL Eppendorf® tubes. Blood digestion status
(fed or not fed) of female mosquitoes will be determined
by external examination of abdomens. Adult mosquitoes
(separated by species and sex) will be stored individually
in absolute 99.5% ethanol in 1.5-mL labeled Eppendorf
tubes. All specimens will be transported to Khon Kaen
University and stored at –80 °C until further processing.
Virus detection in mosquitoes
Virus detection will be performed on adults and
pupae of Ae. aegypti and Ae. albopictus. The heads
and abdomens of adult mosquitoes will be stored sep-
arately. Abdomens will be pooled using a pool size of
5–10 individual abdomens depending on abundance.
Virus detection will first be performed on all pools;
then, if positive, serotype detection will be done on
individual mosquitoes (heads). As heads and abdo-
mens cannot be separated in pupae, virus and sero-
type detection will be done on pools of whole bodies
of pupae. The prevalence of infection in the pupal
population, based on the proportion of positive
pools, will be estimated using previously described
methods [66, 67]. The total RNA will be isolated
from mosquito specimens using Favorgen® reagent
(FavorPrepTM Tissue Total RNA Mini Kit) following
manufacturer instructions. The final solution will be
stored at –80 °C. DENV presence will be confirmed
by real-time quantitative RT-PCR (qRT-PCR) con-
ducted in the LightCycler® 480 Real-Time qPCR Sys-
tem using KAPA SYBR® FAST qPCR Master Mix
(2X) Universal [68]. The Master Mix contains an
optimized MgCl2 concentration. Positive samples will
be submitted to a second specific qPCR to determine
the DENV serotype [69, 70].
Climate data
Climate data, including daily temperature, rainfall,
and humidity data, will be collected from permanent
weather stations located in Khon Kaen and Roi Et
(Department of Meteorology of Thailand). Addition-
ally, four rainfall gauges (three manual and one auto-
matic) and eight temperature-humidity data loggers
(iButtons Hygrochron Loggers, DS1923-F5) will be placed
in each city at suitable locations to capture local
variations.
Data management
Each participating household will be given a 6-digit
identification number (indicating province, village, and
household number) and an identification plate (with
project name and ID number) attached in a secure
location to the house. Each household member will
also receive a unique ID number. Data from house-
hold questionnaires at household enrollment, entomo-
logical collections, blood spot sampling at households
and hospitals (venipuncture for dengue positivity con-
firmation), and disease surveillance data by VHVs will
be collected on paper forms. Data will be securely
stored in a password-protected central database. All
hardcopy and electronic data will be placed in locked
spaces or password-protected computers. Data man-
agement procedures will be detailed in specific
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standard operating procedures and can be requested
from the corresponding author.
Analysis
Index calculations
For all outcomes, baseline measurements will start in
the second half of 2017. Post-intervention measurements
will start in the second half of 2018. The following indi-
ces or rates will be used:
Adult index (AI). Number of adult female Ae.
aegypti and Ae. albopictus per house (combined
species) collected both indoors and outdoors for 15
min at each location (30 min total collection time),
using a battery-driven mechanical aspirator. Collec-
tions will occur once every 4 months in all house-
holds and once every month in three repeat sentinel
households per cluster
Dengue incidence rate (DIR). Number of confirmed
dengue cases divided by observation days of
household populations. All household members with
a fever will be identified during weekly VHV visits
in participating households. Confirmed dengue cases
are those febrile patients with a rapid diagnostic
test (RDT) positive for NS1, IgM, IgG, or
combinations thereof and a subsequent positive
laboratory RT-PCR
Mosquito exposure index (MEI). ΔOD in IgG antibodies
to Ae. aegypti Nterm-34 kDa salivary peptide using
immunoassays, within the sampling scheme described
above. Also the proportion for whom this differential
optical density is above the TR defined above
Infected adult index (IAI). Number of DENV-infected
adult female Ae. aegypti and Ae. albopictus per house
(combined species) collected both indoors and
outdoors for 15 min each, using a battery-driven
mechanical aspirator. DENV presence will be confirmed
by real-time RT-PCR as described above
Adult sticky trap index (ASTI). Number of adult female
Ae. aegypti and Ae. albopictus (combined species)
collected each month using one sticky trap per house
baited with an oviposition attractant hay infusion.
Collections will be done in three selected households
for 7 consecutive days per month
Pupae per person index (PPI). Total number of Aedes
pupae collected in participating households divided by
the number of persons in that household. Collections
will be done once every 4 months in all households and
once every month in three repeat sentinel households
per cluster
Breteau index (BI). Number of immature Aedes positive
containers per 100 houses measured at the cluster level.
Collections will be done once every 4 months in all
households and once every month in three repeat
sentinel households per cluster
Other indices are described in Table 1.
Analysis populations
At the cluster level, analysis will be by intention to treat,
i.e., taking the trial arm as that to which each cluster
was randomized. At the individual level, people will be
taken to have the allocation of the arm in which they are
resident at the time of any data contributed. There will
be no intention-to-treat analysis, unless, for unforeseen
reasons, the Technical Advisory Committee recom-
mends that one be done. A flowchart showing numbers
of clusters and average numbers of households per
cluster over time will be constructed in accordance with
Consolidated Standards of Reporting Trials (CONSORT)
guidelines [71]. For the primary analysis, missing data
may occur if complete clusters decline to continue in
the trial. In this case, the cluster will still be included as
long as any data on the primary outcome are available.
This does introduce a risk of bias in estimating effective-
ness, if loss of clusters is related to performance of the
interventions.
Statistical methods
For the entomological endpoints, clustering will be taken
into account by analyzing summary measures at the level
of cluster. The MEI, expressed as a continuous variable,
is a characteristic of individual people, not houses, and
its main analysis will be by multivariable multilevel
modeling with three levels: cluster, individuals within
clusters, and measurements (time points) within individ-
uals. As before, the exposure of main interest will be the
arm of the trial (intervention versus control). Individual-
level covariates will include age (5–14, 15–25, and > 25
years) and sex. Vector control intervention (i.e., arm of
the trial) will be used as a covariate at cluster level.
Other cluster-level covariates may include abiotic factors
(such as rainfall, temperature, and relative humidity) and
population density. An additional analysis of MEI will be
by summary measures, as for the other endpoints.
For all analyses of summary measures, the arm of the
trial will be the exposure of main interest and will be
included in regression models as a dichotomous variable.
Stratification will be represented by including a dichot-
omous variable for city. Finally, the baseline value of
each outcome, summarized over the pre-intervention
rounds, will be included as a categorical variable, with
the expectation that this will reduce the residual error.
For each outcome variable, the response variable for
the main analysis will be the aggregate value, for each
cluster, of the post-baseline measurements. However, for
the primary endpoint (AI), an additional analysis will
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include the values at each post-baseline time point for
each cluster, and will include an interaction between the
arm of the trial and the time point, with the aim of iden-
tifying a possibly waning effect of the interventions.
Effect of intervention on primary outcome
For each cluster the total number of adult female Ae.
aegypti and Ae. albopictus and the total number of
house visits will be calculated. Taking these as summary
measures, a negative binomial regression will be done
with the number of mosquitoes as the outcome variable
and number of house visits as the exposure (denomin-
ator) variable, i.e., with the logarithm of the number of
houses as the offset. A logarithmic link function will be
used. Hence, the exponential of the coefficient for arm
will be the between-arm ratio in AI according to the
response variable used.
Effect of intervention on secondary outcomes
Dengue incidence in study households will be analyzed
using negative binomial regression. The response vari-
able will be the number of dengue cases per cluster, and
the exposure will be the person-time at risk. Hence, the
analysis will yield rate ratios. Multilevel models will not
be used for this outcome, since the number of cases may
be too small for them to be fitted robustly. The total
number of DENV-infected adult female Ae. aegypti and
Ae. albopictus, i.e., the IAI, will be analyzed in the same
way as the AI. The number of adult mosquitoes per
sticky trap will be analyzed similarly to the AI, with the
exposure variable being the number of traps. This ana-
lysis will yield ratios of the ASTI. Pupae per person
(number of Ae. aegypti pupae/person) will be analyzed
similarly to the AI. The denominator of the PPI is the
number of persons present per cluster summed over
time. For the BI (number of containers with Ae. aegypti
immatures/100 houses) the denominator for each cluster
is the number of house collections during the interven-
tion period. For example, if the same houses are mea-
sured at all time points, the denominator is the number
of houses times the number of time points.
Prediction
The study will attempt to predict dengue incidence over
time using entomological and immunological indices
based on repeated (monthly) field collections. This will
be done in two ways: by predicting the risk of a future
outbreak, and by estimating associations between den-
gue incidence and the indices.
Predict the risk of a future outbreak within a week or
within a longer lead time According to the Ministry of
Public Health, an outbreak is defined as the number of
cases per week exceeding the median number of cases
during the last 3–5 years. We will have data on the
stated indices 1 week every month, as opposed to every
week, so approximately one quarter of the dengue case
series data will be able to be used in this analysis.
Using logistic regression, we will develop a prediction
rule for the outbreak status (i.e., outbreak or not) in a
given week based on data on the indices and on climate,
in the previous week or earlier. Climate variables will
include rainfall amount and frequency and ambient
maximum and minimum temperatures. We will also
consider other variables related to housing type and
socioeconomic status at the spatial level to be predicted.
The aim of the analysis will be to obtain a rule with a
high negative predictive value, i.e., with most of the
negative predictions being borne out, and with few out-
breaks being missed. We will also calculate other operat-
ing characteristics such as sensitivity and specificity. We
will concentrate on trying to predict outbreaks from one
week to the next, i.e., with a lag of 1 week, but will also
assess rules for lags up to 4 weeks.
The accuracy of this prediction rule will be assessed by
developing it on the majority of the data as a “training”
dataset, then evaluating it on the remainder of the data
as a “test” dataset. This reduces the tendency to over-
estimate the accuracy of prediction when the evaluation
is done on the same dataset from which the rule was
developed.
Estimate associations between dengue incidence and
the indices For this method, we will use Poisson regres-
sion and/or time series methods (e.g., autoregressive
integrated moving average (ARIMA)) to relate the num-
ber of cases per week to our study indices and to
climate. Again, the cases in one week will be modeled as
a function of data from the previous week or earlier.
The associations will be measured in terms of rate ratios
or similar coefficients. This analysis will be done using
both the incidence in the public health surveillance
system and the incidence data from the current study.
Associations identified in this analysis may be statistically
significant but not of large enough magnitude to enable
prediction of outbreak status in the previous section.
Harms
This study is deemed of minimal risk for the partici-
pants. Minimal risk is defined as the probability and
magnitude of harm or discomfort anticipated in the
research that are not greater in and of themselves than
those ordinarily encountered in daily life or during the
performance of routine physical or psychological exami-
nations or tests [72]. The vector control interventions,
the pyriproxyfen and spinosad formulations, are recom-
mended by WHO for use in disease vector control and
in drinking water [46, 53–55]. Hence, adverse events
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associated with the products are expected to be few.
However, an adverse event, should one occur, will be
registered by the community-based VHVs through the
weekly visits to all households. The project information
sheet, given to all participants, also contains contact
telephone numbers of the principal investigators and the
Khon Kaen University Ethical Committee should any
questions or reservations arise. Any adverse event during
the trial interventions or trial conduct will be discussed
during weekly meetings of the research team at Khon
Kaen University. Expedited decisions will be made as to
whether any follow-up action is necessary. The opinion
of the Technical Advisory Committee (see the following
section) will be sought should there be adverse events
believed possibly related to the interventions. Based on
these considerations, no criteria have been set for dis-
continuing or modifying the interventions, nor have any
trial stopping guidelines been deemed necessary.
Data monitoring
A Technical Advisory Committee consisting of three
independent researchers assumes the role of a Data
Monitoring Committee (DMC). The duties of the com-
mittee are to stay informed about the progress of the
trial; provide advice to the research team when needed;
assist in solving ethical issues and unforeseen or adverse
events; and determine any potential termination of the
trial. This committee is independent and will not benefit
from the trial or otherwise influence the trial. The terms
of reference of the Technical Advisory Committee can
be accessed from the corresponding author. No interim
analysis is planned.
Auditing
There will be no formal auditing of this trial.
Confidentiality
As described above, the personal information of enrolled
participants will be stored in a safe website ensuring
confidentiality before, during, and after the trial. Analysis
and publication of the results will ensure that no identi-
fiable information is released.
Ancillary and post-trial care
This trial is deemed of minimal risk to study partici-
pants. Therefore, there are no provisions for ancillary or
post-trial care or for compensation to those who suffer
harms from trial participation, beyond the existing Thai
social security system.
Dissemination policy and access to data
Results from this trial will be published in open access,
peer-reviewed journals. The presentation of the final
results of this trial will follow the CONSORT 2010
statement and the extension to cluster-randomized trials
[71] and, if needed, extensions on non-pharmacological
interventions and pragmatic designs [73, 74]. This study
protocol followed the recommendations of items to ad-
dress in a clinical trial protocol (Additional file 1)and
the minimum trial registration information of WHO
(Additional file 2), in addition to what was registered in
the primary ISRCTN registry. Access to the trial dataset
will be made available upon publication of results. Ac-
cess to data will also be archived and made available
through the Norwegian University of Life Sciences and
the Norwegian Centre for Research Data (http://
www.nsd.uib.no/nsd/english/) after the project has offi-
cially ended. Results will be communicated to trial par-
ticipants in easy-to-read local language pamphlets and
through post-project dissemination events. Access to
data collection forms can be requested from the corre-
sponding author.
Discussion
This field trial has a novel combination of aims: to
evaluate simultaneously the efficacy of an innovative
dengue vector control intervention and to develop
methods and indices to anticipate changes in dengue
transmission and predict impending outbreaks. Such
objectives are in harmony with recent published recom-
mendations on global frameworks on vector control and
contingency planning for dengue outbreaks [39, 47] as
well as recommendations from several review papers on
these topics [16, 75]. If successful, results from this study
will provide important information on dengue vector
control and contribute to the further development of
early warning systems and deployment of effective
responses to dengue outbreaks.
Currently, the primary vector control methods used by
the majority of public-funded dengue control programs
are treatment of water storage containers with a larvi-
cide (commonly temephos) and/or peridomestic space
spraying of insecticides. Additionally, source reduction
practices through community-based clean-up campaigns
are common vector control interventions. Although
these standard interventions are recommended by WHO
[5], there is currently no clear evidence that they have
any demonstrable effect on reducing dengue transmis-
sion [7, 9, 33].
A systematic literature review on the effectiveness of
temephos found that as a single community-based inter-
vention it controlled larvae for 2–3 months, depending
on study design, local circumstances, water turnover
rates, and season [7]. However, temephos appears not to
work well in combination with other interventions, pos-
sibly due to an inordinate trust in (or reliance on) its
effectiveness when used alone, poor implementation and
coverage, and low acceptability for its use in drinking
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water [7]. The review concluded that many factors could
influence the effectiveness of temephos, such as the
degree of intervention coverage, quality of implementation
and sustainability, how often treated water is exchanged,
and characteristics and use of the target container itself.
A systematic review on the effectiveness of peridomestic
space spraying (using pyrethroids, pyrethrins, or organo-
phosphates) showed reductions in various entomological
indices; however, the effect dissipated within a few days or
weeks [9]. The authors concluded that the effectiveness of
space spraying in reducing dengue transmission could not
be confirmed and recommended more detailed research
on its utility as a practical public health intervention. Con-
tainer clean-up campaigns might be effective, although
such interventions are often confounded by other simul-
taneous interventions, thus obscuring the effect of the
source reduction campaign itself [75].
It appears that most current dengue vector control
methods lack clear evidence of their effectiveness, which
does not necessarily mean they are ineffective [75].
There have been few well-designed trials, and most have
focused on measuring larval and pupal densities, which
may not be epidemiologically reliable [16]. The current
trial is therefore of great interest to the international
dengue control community, as it will look at a much
wider range of measures, including adult vector dens-
ities. Moreover, the novel use of a pyriproxyfen/spinosad
combination in household water storage containers is a
promising alternative to conventional vector control
methods. Combining the two compounds in a large field
trial under natural conditions has not yet been
attempted. Furthermore, the two compounds comple-
ment each other in that one targets the mosquito larval
stage (spinosad) and the other the pupal stage (pyriprox-
yfen); thus, they potentially provide long-term control in
the environment and disease reduction [42, 44]. In
Vietnam, pyriproxyfen used together with insecticide-
treated covers of water storage containers successfully
inhibited mosquito breeding for 5 months [76]. A small,
simulated field trial using a pyriproxyfen/spinosad mix-
ture reported that the mixture was effective for at least 8
months compared with 3 months for spinosad alone and
5 months for pyriproxyfen alone. In natural breeding
sites the mixture remained effective for 4.5 months [42].
Both compounds are not toxic to humans or most non-
target fauna [45, 46]. Pyriproxyfen also has an additional
advantage in that it can be disseminated to other larval
habitats by adult mosquitoes [30–32].
This trial is also designed to identify practical and sen-
sitive entomological and immunological indicators for
prediction of dengue transmission and increased risk for
dengue outbreaks. The more accurate, timely, and site-
specific the prediction, the greater the likelihood a
control response would mitigate, if not prevent, the
outbreak from occurring. The originality of this trial is
that virological and immunological methods are used in
combination with standard entomological measures in
both intervention and control clusters. The Peru study
mentioned previously [17] investigated the relationship
between indicators of mosquito abundance and DENV
infection. Although, it is probably one of the most
comprehensive studies to date, such abundance-based
indicators are not likely to be sensitive enough to detect
changes in intensity of transmission. A better indicator
would be to monitor adult mosquitoes for dengue viral
infection, similarly as is done to assess malaria transmis-
sion risk using the entomological inoculation rate. RDTs
can be used as a simple method to detect DENV antigen
in mosquitoes [77, 78]. New methods to monitor
DENV-infected adult Aedes densities using various trap-
ping designs and RDTs have been proposed as a new
paradigm in Aedes surveillance [79, 80].
Another potentially promising indicator is to measure
the exposure of people to mosquito bites using human
antibody response to mosquito salivary protein. A recent
study carried out along the Thai-Myanmar border areas
demonstrated that levels of IgG response were positively
associated with anopheline vector abundance and the
entomological inoculation rate [81]. The antibody
response to Ae. aegypti whole saliva has been shown to
be a quantitative biomarker of human exposure in Africa
and South America [82, 83]. More recently, a salivary
peptide (Nterm-34 kDa) was identified as a specific
Aedes biomarker [84, 85]. The IgG immune response to
Nterm-34 kDa salivary peptide is not expected to last for
more than 15–30 days; hence, it represents a relevant
temporal biomarker to assess recent relative exposure of
humans to Aedes bites [84]. This peptide was used suc-
cessfully as a short-time indicator to evaluate vector
control interventions against Aedes exposure in Réunion
Island [86].
In this trial, DENV detection in adults and pupae will
be assessed in relation to the number of recent and sub-
sequent confirmed dengue incidents in humans in the
same locality. Human exposure to Aedes bites measured
by IgG antibody response will be examined for correl-
ation with dengue cases. Data will be analyzed to include
socioeconomic factors and influence of environmental
and seasonal fluctuations, such as rainfall, relative
humidity, and ambient temperature. These parameters
and specific measures have so far not been fully inte-
grated in epidemiological risk assessments and epi-
demic forecasting.
The permanent staff of local public health depart-
ments, sub-district hospitals, and VHVs will collect
data for all listed outcomes, thereby minimizing in-
volvement of full-time trial project staff. This is
intended, as much as possible, to allow national
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authorities to emulate the project procedures in
follow-on surveillance and intervention activities or
adoption of these methods into routine vector control
program activities. The exception to this is molecular-
based assay confirmation of DENV in human blood
and mosquitoes and human antibody response to Ae.
aegypti salivary peptides; this testing will be con-
ducted by project staff.
Study limitations
Several potential limiting factors may affect study out-
comes. High spatial and temporal variation in dengue
transmission dynamics may result in an insufficient
number of incident infections to allow reliable associa-
tions between indices and dengue risk. This is why
collections will be conducted over a 2-year period and in
two urban areas to increase the potential of witnessing
an upsurge in transmission as opposed to an interepi-
demic period. Nevertheless, the sample size required to
detect significant differences in dengue incidence
between the intervention and control arms was deemed
unfeasibly large, thus relegating dengue incidence as a sec-
ondary outcome. Conversely, a dengue outbreak could
likely overwhelm data collection systems used in the trial
and further compel public health authorities to intervene
with standard vector control interventions on a broad
scale, thus potentially interfering with study outcomes. If
outcome measures are substantially suppressed, this
would negatively affect the power of the study.
Lastly, the proportion of asymptomatic (inapparent)
and infectious persons in the study area may affect pre-
diction outcomes, because they will not be captured by
the data collection procedures used in the trial, although
they may contribute to transmission [87]. Although the
ratio of asymptomatic to symptomatic cases can be as
high as 14:1 or higher, the epidemiological role of
asymptomatic infections remains unclear [88].
Trial status
At the time of submission of this manuscript, the trial has
enrolled village clusters, requested household participation,
and started baseline data collections in Khon Kaen (but not
yet in Roi Et). Recruitment of patients has not started.
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